伊立替康在晚期胃癌化疗中的疗效评价

Evaluation of Efficacy of Irinotecan Chemotherapy in Advanced Gastric Carcinoma

目的通过对晚期胃癌病例的化疗疗效进行对比分析,探讨伊立替康在晚期胃癌化疗中的应用价值。方法选取本院2010年6月~2012年6月收治的80例晚期胃癌患者,随机分为实验组和对照组,每组各40例。实验组采用伊立替康联合奥沙利铂进行治疗;对照组采用5-FU联合奥沙利铂进行治疗。治疗2个周期后,观察两组疗效。结果实验组和对照组的治疗总有效率分别为67.5%和47.5%,两组方案的疗效差异具有统计学意义（P〈0.05）;实验组和对照组的不良反应率分别为40.0%和67.5%,且主要发生在肠道及骨髓抑制上,两者差异具有统计学意义（P〈0.05）。结论采用伊立替康治疗晚期胃癌不仅具有显著的疗效,而且用药后不良反应较少,患者的耐受性较好。

Objective To By comparing the efficacy of chemotherapy for advanced gastric cancer cases, discusses the vertical application value for kang chemotherapy in advanced gastric cancer. Methods Select our June 2010 to June 2012 treated 80 cases of patients with advanced gastric cancer, were randomly divided into experimental group and control group, 40 cases in each group. Used by the state for kang joint oxaliplatin into treatment; The control group with 5-FU joint oxaliplatin into treatment. 2 cycle after treatment, observation curative effect of the two groups. Results The experimental group and the control group total effective rate were 67.5% and 47.5% respectively, the curative effect of two groups of solution differences statistically significant（P〈0.05）, Experimental group and control group in the adverse reaction rate were 40.0% and 67.5% respectively, and mainly occurs in the gut and bone marrow suppression, both statistically significant difference（P〈0.05）. Conclusion Using the vertical for treatment of advanced gastric cancer not only has significant curative effect, and the drug adverse reaction is less, the patient＇s tolerance is good, is worth popularization and application in clinic.